Abstract
Increasing experimental studies indicate the existence of novel molecular targets for cannabinoid ligands and recently it has been suggested that the orphan G-protein coupled receptor, GPR55 can be activated by a range of endogenous, plant and synthetic cannabinoids. However, to date, the most potent ligand identified for GPR55 is the endogenous phospholipid, lysophosphatidylinositol (LPI). GPR55 is thought to link predominantly to G-protein α13, where it promotes Rho-dependent signalling. Additional events downstream of GPR55 include activation of ERK-MAP kinase and Ca2+ release from stores, as well as the induction of a number of transcription factors. Although GPR55 has only a low sequence identity with the CB1 or CB2 cannabinoid receptors, it clearly interacts with certain cannabinoid ligands. However, the nature and scope of these effects are presently unclear and they may be influenced by the assay and cellular background used for their study. This article reviews the current status of GPR55 pharmacology and its putative endogenous ligand, LPI.
Keywords: GPR55, Cannabinoid, Lysophosphatidylinositol
Current Topics in Medicinal Chemistry
Title: GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?
Volume: 10 Issue: 8
Author(s): Tapio Nevalainen and Andrew J. Irving
Affiliation:
Keywords: GPR55, Cannabinoid, Lysophosphatidylinositol
Abstract: Increasing experimental studies indicate the existence of novel molecular targets for cannabinoid ligands and recently it has been suggested that the orphan G-protein coupled receptor, GPR55 can be activated by a range of endogenous, plant and synthetic cannabinoids. However, to date, the most potent ligand identified for GPR55 is the endogenous phospholipid, lysophosphatidylinositol (LPI). GPR55 is thought to link predominantly to G-protein α13, where it promotes Rho-dependent signalling. Additional events downstream of GPR55 include activation of ERK-MAP kinase and Ca2+ release from stores, as well as the induction of a number of transcription factors. Although GPR55 has only a low sequence identity with the CB1 or CB2 cannabinoid receptors, it clearly interacts with certain cannabinoid ligands. However, the nature and scope of these effects are presently unclear and they may be influenced by the assay and cellular background used for their study. This article reviews the current status of GPR55 pharmacology and its putative endogenous ligand, LPI.
Export Options
About this article
Cite this article as:
Nevalainen Tapio and J. Irving Andrew, GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?, Current Topics in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/156802610791164229
DOI https://dx.doi.org/10.2174/156802610791164229 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres
Anti-Cancer Agents in Medicinal Chemistry Editorial: Brain Imaging and Automatic Analysis in Neurological and Psychiatric Diseases – Part II
CNS & Neurological Disorders - Drug Targets Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy Monocarboxylate Transporter 1 in Brain Diseases and Cancers
Current Drug Metabolism TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Genes Involved in Apoptosis Regulation: Implications for Cancer Therapy
Current Genomics